Coeptis Therapeutics Holdings Inc
COEP
查看详细走势图
14.660USD
+0.020+0.14%
收盘 12/19, 16:00（美东）报价延迟15分钟
75.61M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.14%
5天
-3.11%
1月
-12.79%
6月
+93.92%
今年开始到现在
+166.55%
1年
+418.02%
查看详细走势图
TradingKey Coeptis Therapeutics Holdings Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Coeptis Therapeutics Holdings Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名219/404位。机构持股占比非常高，中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Coeptis Therapeutics Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
--
目标均价
--
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Coeptis Therapeutics Holdings Inc亮点
亮点风险
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
估值低估
公司最新PE估值-4.00，处于3年历史低位
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值50.67K
Coeptis Therapeutics Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Coeptis Therapeutics Holdings Inc简介
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
公司代码COEP
公司Coeptis Therapeutics Holdings Inc
CEOMehalick (David)
网址https://coeptistx.com/
常见问题
Coeptis Therapeutics Holdings Inc(COEP)的当前股价是多少？
Coeptis Therapeutics Holdings Inc(COEP)的当前股价是 14.660。
Coeptis Therapeutics Holdings Inc的股票代码是什么？
Coeptis Therapeutics Holdings Inc的股票代码是COEP。
Coeptis Therapeutics Holdings Inc股票的52周最高点是多少？
Coeptis Therapeutics Holdings Inc股票的52周最高点是21.410。
Coeptis Therapeutics Holdings Inc股票的52周最低点是多少？
Coeptis Therapeutics Holdings Inc股票的52周最低点是2.310。
Coeptis Therapeutics Holdings Inc的市值是多少？
Coeptis Therapeutics Holdings Inc的市值是75.61M。
Coeptis Therapeutics Holdings Inc的净利润是多少？
Coeptis Therapeutics Holdings Inc的净利润为-9.81M。
现在Coeptis Therapeutics Holdings Inc(COEP)的股票是买入、持有还是卖出？
根据分析师评级，Coeptis Therapeutics Holdings Inc(COEP)的总体评级为--，目标价格为--。
Coeptis Therapeutics Holdings Inc(COEP)股票的每股收益（EPS TTM）是多少
Coeptis Therapeutics Holdings Inc(COEP)股票的每股收益（EPS TTM）是-3.661。
相关品种
